Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
News|Articles|January 20, 2026
Zenocutuzumab Offers Durable Benefit After Progression in NRG1+ GI Tumors
Author(s)Andrea Eleazar, MHS
Fact checked by: Paige Britt, Kelly King
Listen
0:00 / 0:00
Key Takeaways
- Zenocutuzumab demonstrated a 35% objective response rate in NRG1+ gastrointestinal tumors, with 1 complete and 5 partial responses, and 8 achieving stable disease.
- The clinical benefit rate was 65% for patients with complete or partial response or stable disease for at least 24 weeks.
Zenocutuzumab shows promising efficacy in advanced NRG1+ pancreatic and cholangiocarcinoma, offering hope for patients after disease progression.
Advertisement
Zenocutuzumab (Bizengri) continued to provide sustained clinical benefit and disease control in patients with advanced NRG1 fusion-positive (NRG1+) pancreatic adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) who continued therapy beyond progression, according to a post hoc analysis of the phase 1/2 eNRGy trial (NCT02912949).1
The analysis assessed the efficacy and safety of zenocutuzumab in a subgroup of 17 patients with NRG1+ gastrointestinal tumors, including 12 patients with PDAC and 5 patients with CCA, who received at least 3 doses of therapy after progressive disease. The objective response rate (ORR) among this group was 35%, including 1 complete response, 5 partial responses, and 8 patients achieving stable disease.
Furthermore, the analysis reported a promising clinical benefit rate, with 65% of patients reporting a complete or partial response or stable disease for at least 24 weeks. The safety analysis also revealed zenocutuzumab’s ongoing favorable tolerability profile, with no adverse event (AE)-related treatment discontinuation. These results were presented at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
“These findings highlight an important therapeutic opportunity for patients with NRG1[+] pancreatic and biliary cancers, which are often difficult to treat,” Alison M. Schram, MD, of Memorial Sloan Kettering Cancer Center and lead author, said in a news release.1 “In this analysis, zenocutuzumab provided ongoing benefit after radiographic progression, including multiyear disease control in some patients.”
Zenocutuzumab in GI Cancers
Zenocutuzumab is an immunoglobulin G1 bispecific antibody simultaneously targeting HER2 and HER3.2 In December 2024, zenocutuzumab received
Most recently, the FDA granted the agent
About the eNRGy Trial
The eNRGy trial is a multicenter, open-label, dose-escalation and -expansion trial designed to assess the safety, tolerability, immunogenicity, and antitumor activity of zenocutuzumab in patients with solid tumors harboring an NRG1 fusion.3 The trial’s primary end point is ORR; secondary end points include duration of response (DOR), clinical benefit rate, progression-free survival (PFS), and safety.
According to interim data presented last year at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, the ORR among 19 evaluable patients was 37%, with a median DOR of 7.4 months and clinical benefit rate of 58%.4 The PFS was reported at 9.2 months.
The safety profile was characterized by mostly grade 1 or 2 AEs, with no treatment-related discontinuations.
REFERENCES
1. Continued zenocutuzumab treatment beyond progression shows benefit in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: New results from the eNRGy trial presented at ASCO GI. News release. Partner Therapeutics. January 9, 2026. Accessed January 20, 2026. https://tinyurl.com/5ypwksvw
2. Schram AM, Odintsov I, Espinosa-Cotton M, et al. Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. Cancer Discov. 2022;12(5):1233-1247. doi:10.1158/2159-8290.CD-21-1119
3. A study of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy). ClinicalTrials.gov. Updated April 29, 2025. Accessed January 20, 2026. https://clinicaltrials.gov/study/NCT02912949
4. Zenocutuzumab-zbco granted FDA breakthrough therapy designation for NRG1+ cholangiocarcinoma; data highlighting potential of zenocutuzumab-zbco in NRG1+ cholangiocarcinoma to be presented at AACR-NCI-EORTC. News release. Partner Therapeutics. October 23, 2025. Accessed January 20, 2026. https://tinyurl.com/3yrjmdnu
Advertisement
Related to this article
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.
New 177Lu-dotatate radioligand therapy expands options for SSTR+ GEP-NETs, backed by NETTER-1 efficacy and key safety guidance.
The FDA has recommended conducting a new trial showing an OS benefit with tovecimig in biliary cancer before submitting a BLA.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5